{
    "organizations": [],
    "uuid": "5782fcee066eac247075002bfe326a348f5aec86",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-surface-pharmaceuticals-inc-announ/brief-surface-pharmaceuticals-inc-announces-20-million-series-a-financing-from-flying-l-partners-idUSASC0A28Q",
    "ord_in_thread": 0,
    "title": "BRIEF-Surface Pharmaceuticals, Inc. Announces $20 Million Series A Financing From Flying L Partners",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 15 (Reuters) - Imprimis Pharmaceuticals Inc:\n* SURFACE PHARMACEUTICALS, INC. ANNOUNCES $20 MILLION SERIES A FINANCING FROM FLYING L PARTNERS\n* IMPRIMIS PHARMACEUTICALS - SURFACE PHARMA INTENDS TO USE PROCEEDS OF FINANCING TO ADVANCE CLINICAL DEVELOPMENT PROGRAMS FOCUSED ON OCULAR SURFACE DISEASE Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\nOur Standards: The Thomson Reuters Trust Principles. ",
    "published": "2018-05-15T19:39:00.000+03:00",
    "crawled": "2018-05-16T18:53:06.015+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "imprimis",
        "pharmaceutical",
        "inc",
        "surface",
        "pharmaceutical",
        "announces",
        "million",
        "series",
        "financing",
        "flying",
        "l",
        "partner",
        "imprimis",
        "pharmaceutical",
        "surface",
        "pharma",
        "intends",
        "use",
        "proceeds",
        "financing",
        "advance",
        "clinical",
        "development",
        "program",
        "focused",
        "ocular",
        "surface",
        "disease",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}